NCT04393220View on ClinicalTrials.gov

Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 11, 2020

Primary Completion Date

July 30, 2021

Study Completion Date

August 31, 2021

Conditions
Progress Free Survival (PFS) and Overall Survival (OS)
Interventions
DRUG

Bevacizumab Injection

15mg/kg (Q3W)

DRUG

Nivolumab

nivolumab 480 mg IV infusions for 30 minutes q4w

Trial Locations (1)

510665

Fuda Cnacer Hospital, Guangzhou

All Listed Sponsors
lead

Fuda Cancer Hospital, Guangzhou

OTHER

NCT04393220 - Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter